AbbVie Inc.

- Announced a $1.4 billion pharmaceutical manufacturing campus in North Carolina. - Committed $380 million for two new manufacturing plants in North Chicago. - Part of a larger $100 billion, multi-decade capital investment plan. - Investments aimed at supporting future launches in immunology, oncology, and obesity therapeutics. - Strategic R&D advances include the closure of the Remagen agreement for a novel PD-1 VEGF bispecific antibody. - Continued expansion of oncology and immunology assets to drive long-term growth. - Active business development focus on acquiring external innovation, particularly in immunology and neuroscience.

- AbbVie reported net interest expense of $645 million for the quarter. - The full-year adjusted net interest expense is now expected at $2.7 billion, which is $100 million lower than prior expectations due to favorable debt rates. - There is no explicit mention of new fundraising through debt or equity in the provided transcript. - Management highlighted strong financial flexibility and significant capital investments, such as a $1.4 billion manufacturing campus in North Carolina and $380 million for two new plants in North Chicago. - AbbVie continues to invest heavily in R&D and business development to support its growth outlook. - No announcements about upcoming debt or equity issuances were made during this call.

- AbbVie raised full-year adjusted EPS guidance by $0.12 to $14.08–$14.28, reflecting confidence in strong growth. - Full-year revenue outlook increased by $300 million to $67.3 billion. - Skyrizi revenue guidance increased by $100 million to $21.6 billion; Rinvoq guidance also raised by $100 million to $10.2 billion. - Immunology sales up significantly, with Skyrizi up 29.2% and Rinvoq up 20.2% operationally, expected to sustain growth. - New indications for Rinvoq (vitiligo, alopecia areata) and additional Skyrizi gastroenterology approvals expected to drive further volume and revenue growth. - Interim obesity therapy ABBV-295 shows promising early data (10% weight loss in 12 weeks) supporting future commercial opportunity. - Combination therapies like Skyrizi plus ABBV-382 demonstrating high remission rates, indicating potential for transformative efficacy. - Oncology portfolio expansion via new assets expected to provide incremental growth. - Aesthetics business stable with Botox growth offsetting dermal filler softness; long-term potential remains. - Management expects peak sales upside beyond current consensus for Skyrizi and Rinvoq.

- AbbVie raised its full-year adjusted EPS guidance by $0.12 to a range of $14.08 to $14.28, reflecting strong momentum. - Adjusted operating margin ratio is projected at 40.8% of sales, with an anticipated adjusted operating margin of 50% for Q2. - Full-year revenue outlook upgraded to $67.3 billion, up $300 million from prior expectations. - Skyrizi revenue guidance increased by $100 million to $21.6 billion; Rinvoq raised by $100 million to $10.2 billion. - Neuroscience revenue forecast raised by $300 million to $11.3 billion. - Management expects peak potential for Skyrizi and Rinvoq to significantly exceed current analyst estimates. - Continued strong growth and solid earnings are supported by robust sales in immunology and neuroscience and pipeline advancements. - Adjusted R&D and SG&A expenses are 15.1% and 22.7% of sales, respectively, supporting future innovation. - Improved net interest expense outlook, now expected at $2.7 billion for the year, benefiting profitability.

The provided transcript does not explicitly mention current or expected orderbook or pending orders for AbbVie. However, key points related to demand and sales outlook include: - Strong demand across AbbVie's portfolio with Skyrizi and Rinvoq leading growth. - Skyrizi on track for ~30% global sales growth in Crohn’s disease and ulcerative colitis. - Rinvoq sales up 20.2% operationally with high-teens prescription growth especially in ulcerative colitis. - Skyrizi’s combination studies show promising efficacy, supporting future commercial potential. - Early-stage obesity therapy ABBV-295 shows encouraging weight loss data supporting monthly dosing. - Aesthetics business stable with Botox sales up 17%; Juvederm facing market headwinds. - Management expects peak potential for Skyrizi and Rinvoq to exceed current analyst estimates. - Full-year revenue guidance upgraded to $67.3 billion, reflecting strong commercial momentum. No direct figures on orderbook or pending orders are detailed in the transcript.